Compare Abeona Therapeutics Inc (ABEO) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vale SA — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Vale SA trades at $14.14 (market cap $62.60B). The key difference: Vale SA is far larger — about 167.7× Abeona Therapeutics Inc's market cap, and Vale SA pays a 8.57% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VALE | |
|---|---|---|
Market Cap | $373.32M | $62.60B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $17.82 |
52-Week Low | $4.17 | $9.53 |
Enterprise Value | $228.22M | $79.52B |
Dividend Yield | — | 8.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VALE trades at $14.69, down 2.0% over the past day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. Revenue for 2025 was $38.40 billion with a net income margin of 7.21%, while cash flow from operations remained strong at $8.80 billion. Recent news includes a board governance dispute and a $2.56 billion decarbonization investment plan announced on June 15, 2026 (Reuters).
The outlook is cautious with a consensus analyst price target of $18.30, implying potential upside, but risks include volatile iron ore prices, rising debt-to-asset ratios, and execution challenges. Earnings growth and cost management are key catalysts for stock performance amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
